Combination treatment using thymosin alpha 1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice.
Garaci. E E; Mastino. A A; Pica. F F; Favalli. C C
Key Findings
- Thymosin‑alpha‑1 plus interferon after cyclophosphamide cleared lung tumors in mice
- The combo dramatically increased natural killer cell activity and tumor‑infiltrating lymphocytes
- Single agents alone were ineffective or only slightly effective
Practical Outcomes
- The results are promising for cancer‑immune therapy but are limited to a mouse model. No safe human dosing or protocol is established, so it isn’t ready for self‑use. It suggests that combining immune‑boosting peptides with interferon after chemo could be worth clinical testing, not DIY experimentation.
Summary
In mice with lung cancer, giving thymosin‑alpha‑1 for four days, then a single dose of interferon after a chemotherapy shot, made the tumors disappear and helped the mice live longer. The combo boosted natural killer cells and brought more immune cells into the tumors, while each drug alone did little.
Abstract
A combination treatment with thymosin alpha 1 (200 micrograms/kg) for 4 days, followed by a single injection of murine interferon alpha/beta (3 x 10(4) international units/mouse). starting 2 days after cyclophosphamide treatment (200 mg/kg, single injection) demonstrated a dramatic and rapid disappearance of tumor burden in mice bearing Lewis lung carcinoma (3LL) tumor. The effectiveness of this new chemoimmunotherapy protocol was evident even on the long-term survival in a high percentage of animals, and was statistically significant when compared to treatment with the single agents in conjunction with chemotherapy or to chemotherapy itself. The same combination immunotherapy treatment strongly stimulated natural killer activity and cytotoxicity against autologus 3LL tumor cells in 3LL-tumor-bearing mice treated with cyclophosphamide, whereas treatments with each agent singly did not alter or only slightly modified the cytotoxic activity towards Yac-1 or 3LL target cells. Selective depletion with antibodies showed that killer cells stimulated by combination chemoimmunotherapy treatment bear phenotypic characteristics of asialo-GM1-positive cells. A histological study has shown a high number of infiltrating lymphoid cells in the tumors obtained from mice treated with combination chemoimmunotherapy.
Study Information
pubmed
1990
10.1007/bf01771450